Stay updated on Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.

Latest updates to the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe page now presents the clinical-trial record for radiation and chemotherapy with ipilimumab followed by nivolumab for unresectable stage III NSCLC, including its terminated status, eligibility criteria, study locations, treatment plan, outcomes, and posted results.SummaryDifference52%

- Check14 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0, while the study page remains inaccessible with a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide banner announces an NIH transition notice about using “Super Intelligence” in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating the record is currently inaccessible. The visible layout shows the standard site chrome and an error message, replacing the prior study details and related information.SummaryDifference19%

Stay in the know with updates to Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiation+Chemo+Ipilimumab+Nivolumab in Stage III NSCLC Clinical Trial page.